Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update. by Floriani, Carmen et al.
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
Clinical Update
Subclinical thyroid dysfunction and
cardiovascular diseases: 2016 update
Carmen Floriani1, Baris Gencer2, Tinh-Hai Collet3,4, and Nicolas Rodondi1,5*
1Department of General Internal Medicine, Inselspital, Bern University Hospital, Freiburgstrasse 8, 3010 Bern, Switzerland; 2Cardiology Division, Geneva University Hospital, Rue
Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland; 3Service of Endocrinology, Diabetes and Metabolism, University Hospital of Lausanne, Av. de la Sallaz 8, 1011 Lausanne,
Switzerland; 4University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke’s Hospital, Hills Road, CB2 0QQ,
Cambridge, UK; and 5Berner Institut für Hausarztmedizin BIHAM, Gesellschaftsstrasse 49, 3012 Bern, Switzerland
Received 21 April 2016; revised 8 July 2016; editorial decision 28 September 2016; accepted 26 January 2017; online publish-ahead-of-print 27 February 2017
Subclinical thyroid dysfunction comprises subclinical hypothyroidism (SHypo), defined as elevated thyroid-stimulating hormone (TSH) by
normal free thyroxine (FT4), and subclinical hyperthyroidism (SHyper) with decreased or undetectable TSH and normal FT4. Up to 10%
of the elderly have SHypo, which is usually asymptomatic. Individual participant data (IPD) analyses of prospective cohort studies from the
international Thyroid Studies Collaboration show that SHypo is associated with increased coronary heart disease (CHD) mortality [hazard
ratio (HR) 1,58 for TSH >_ 10 mIU/L, 95% CI 1.10–2.27), as well as increased risk of stroke, and heart failure (HF) for both higher and
lower TSH. Small studies found that SHypo affects carotid intima media thickness (CIMT), diastolic function, peripheral vascular resistance,
endothelial function, and lipid profile. SHyper is associated with increased risk of atrial fibrillation (AF) (HR 1.68, 95% CI 1.16–2.43) and
CHD events (HR 1.21, 95% CI 0.99–1.46). The TSH threshold for initiating treatment is unclear. In the absence of large randomized con-
trolled trials, the best evidence suggests SHypo therapy should be started at TSH >_ 10 mIU/L, and SHyper therapy at TSH < 0.1 mIU/L.
Recommendations on screening are discordant, but most guidelines advocate that thyroid function should be checked in those at risk for
hypothyroidism, those over 60, and those with known CHD and HF. This review updates current evidence on the association between
thyroid dysfunction and cardiovascular disease, as well as on screening and treatment of subclinical thyroid dysfunction.
...................................................................................................................................................................................................
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Clinical and epidemiological
relevance of subclinical thyroid
dysfunction
Subclinical thyroid dysfunction comprises subclinical hypothyroidism
(SHypo) and subclinical hyperthyroidism (SHyper). SHypo is defined
as thyroid-stimulating-hormone (TSH) above the normal range, with
normal free thyroxine (FT4).1 SHypo can reach up to 10%, and is
most prevalent among elderly women.2 Recent data show that
SHypo is associated with coronary heart disease (CHD),3–7 heart fail-
ure (HF),8 and stroke.9 Endogenous SHyper is defined as low or un-
detectable TSH, with FT4 and free triiodothyronine (FT3) within the
reference range. SHyper is associated with increased CHD events,
CHD mortality, and incident atrial fibrillation (AF).10 In the National
Health and Nutrition Examination Survey III, 0.7% of participants had
TSH < 0.1 mIU/L and 1.8% < 0.4 mIU/L.11 The prevalence of SHyper
depends on age, sex and iodine intake.12 Exogenous SHyper is caused
by thyroid hormone replacement in up to 20% of treated patients. A
retrospective cohort study on levothyroxine prescription among 52
298 participants showed that after 5 years of treatment, 5.8% of par-
ticipants had TSH < 0.1 mIU/L.13
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Biochemical definition of
subclinical thyroid dysfunction and
variations according to population
characteristics
Third generation TSH chemiluminometric assay is widely used
and allows to detect changes of 0.01 mIU/L. TSH within the hyper-
thyroid range can now reliably be distinguished from euthyroid, al-
though there is still debate over the lower limit of the TSH reference
range.14 For SHypo, controversy remains about the TSH range and
upper limit.15–17 Most guidelines set an upper limit of 4.4–5.0 mIU/L,
but the majority of euthyroid individuals fall between 0.4 and 2.5 mIU/
L, depending on their iodine intake.2,18 Observational studies show
that TSH tends to increase with age,19,20 which seems to be a physio-
logical process and a marker of frailty rather than a pathological devel-
opment. There might be a danger of SHypo overdiagnosis, especially
in the elderly, but age-based cut-off points have not yet been stand-
ardized.21 The underlying mechanisms leading to overt hypothyroid-
ism, characterized by TSH above and FT4 below the reference range,
are still not clear, though, one study described the average yearly pro-
gression rate as ranging from 2 to 6%, depending on the presence of
antithyroid peroxidase antibodies and on initial TSH.22
General pathophysiological
aspects
Each individual probably has a specific, genetically determined set point
for the hypothalamic-pituitary-thyroid axis.23–25 A Danish twin study
found heritability accounted for 64% of TSH variation (95% CI: 57–
70%), 65% of FT4 variation (95% CI: 58–71%), and 64% of FT3 variation
(95% CI: 57–70%).25 FT4 plays the most important role in regulating
TSH secretion (Figure 1). Minimal changes in FT4 have a strong effect on
TSH secretion,26 but the earlier description of the regulating mechanism
as a log-linear relationship between TSH and FT4 has been challenged.
Mathematical models show the relationship is better represented by
two overlapping sigmoid curves, where TSH is expected to be higher
for men and the elderly.27 Symptoms of thyroid dysfunction are some-
times nonspecific: fatigue and depression are frequent, as are dyslipidae-
mia, weight gain, constipation. More extreme symptoms are pericardial
effusion and myxoedema. Subjects with SHypo rarely report the full
cluster of symptoms, but frequently report symptoms like tiredness,28
cramps, weakness, and myalgia.29 Clinical manifestation of SHyper is less
pronounced than it is for overt hyperthyroidism (characterized by low
or undetectable TSH and FT3/FT4 above the reference range). For
SHyper, symptoms may be absent or similar to overt hyperthyroid-
ism12: increased metabolic basal rate and thermogenesis (systemic
symptoms),12 sinus tachycardia, AF, congestive HF, and peripheral vaso-
dilation with ankle oedema (cardiac symptoms).30,31
Thyroid dysfunction and the
heart: pathophysiological
mechanisms
Peripheral deiodinases convert thyroxine to triiodothyronine, the active
form of thyroid hormones. Within the cell, triiodothyronine is a
transcriptional and extranuclear modulating factor that stimulates activity
of cardiac myocytes and vascular smooth muscle cells. Triiodothyronine
regulates the expression of structural and functional proteins, like calcium-
activated ATPase and phospholamban, at DNA level.32 Triiodothyronine
also regulates the intracellular calcium concentration, and determines sys-
tolic contractile function and diastolic relaxation. Triiodothyronine inter-
acts directly with sodium, potassium, and calcium channels, modulating
ionic exchange between intra- and extracellular compartments, and im-
proving cardiac inotropy and chronotropy32,33 (Figure 2).
Overt hypothyroidism can cause cardiac anomalies, including
(i) rhythmic disorders like bradycardia and atrioventricular block30;
(ii) myocardial abnormalities like impaired systolic function, increased
left ventricular (LV) diastolic filling, diastolic dysfunction with im-
paired cardiac relaxation, pulmonary hypertension, atrial stiffness,
pericardial effusion; and, (iii) vascular disturbances like endothelial
dysfunction and arterial hypertension33 (Figure 3). LV stroke volume
can be decreased by bradycardia, increased diastolic pressure, atrial
stiffness, and poor contractility, which can also aggravate HF.32,34 LV
ejection fraction is the most widely reported outcome in studies on
HF and CHD for risk stratification and medical decision.35 Global
heart function is the result of the interaction of myocardial contractil-
ity, preload (end-diastolic volume), heart rate, and afterload. Because
half of patients with HF events have preserved ejection fraction,
guidelines recommend to use additional endpoints of diastolic func-
tion and LV pressing filling, such as transmitral inflow patterns (E-,
A-wave, and E/A), pulsed TVI-derived early diastolic velocity of the
mitral annulus (E/e’ ratio) and left atrial volume.35
In SHypo anomalies are more common at higher TSH and among
the elderly.36 It is specifically associated with diastolic dysfunction.
Case-control studies found patients with SHypo have prolonged
Isovolumic Relaxation Time (IRT), increased A wave, and diminished
E/A ratio.36 In the Cardiovascular Health Study, the 3044 patients
>_ 65 years with TSH >_ 10 mIU/L had higher baseline peak E velocity
(0.80 m/s) than those with normal TSH (0.72 m/s, P = 0.002).37 In
addition, each 0.1 m/s increase in E wave velocity was associated with
T3, T4
T4, (T3)
Peripheral
tissues
Thyroid gland
Pituitary gland
Hypothalamus
TRH+
+
TSH
-
-
Figure 1 Simplified illustration of thyroid hormones homeostasis.
TRH, thyrotropin-releasing hormone; TSH, thyroid-stimulating hor-
mone; T4, thyroxine; T3, triiodothyronine.
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higher risk of HF events (HR 1.14, 95% CI 1.08–1.18, P < 0.001), es-
pecially with TSH >_ 10 mIU/L (HR 1.45, 95% CI 1.20–1.76).37
Overt hyperthyroidism affects the cardiac pacemaker function and
contractility.31,38 SHyper, on the other hand, is associated with more
premature atrial and ventricular beats, higher mean heart rate over
24 h,12 and increased risk of AF.10 Cardiac changes in hyperthyroidism
can be explained by the positive inotropic, chronotropic, and lusitropic
effects of triiodothyronine that might be associated with higher cardio-
vascular morbidity and mortality.12 The effects of thyroid hormones on
the heart in hyperthyroidism mimic a hyper-adrenergic state although
there is no evidence that thyroid hormones affect the responsiveness
of the heart to catecholamines (Figure 3). Some b-adrenergic elements
in cardiomyocytes like the b1-adrenergic receptors and the adenylate
cyclase are regulated by the thyroid hormones.31
Subclinical thyroid dysfunction
and surrogate cardiovascular
markers
Carotid Intima Media Thickness (CIMT) is a surrogate cardiovascular
endpoint39–41 associated with both SHyper and SHypo.12 CIMT may
be an independent predictor for cardiovascular events, although its
usefulness for classifying risk is still unclear.42 A meta-analysis found
that each 0.10 mm IMT increase corresponded to an increased RR
for myocardial infarction of 1.15 (95% CI 1.12–1.17) and for stroke of
1.18 (95% CI 1.16–1.21).43
In a case-control study, CIMT was significantly higher among
the 36 patients with SHypo (0.66 mm ± 0.10) than the 32 controls
(0.57 mm ± 0.08).39 In a double-blind cross-over trial, 100 patients
(mean age 53.8 years) with no prior thyroid dysfunction were
randomized to 100 mg levothyroxine or placebo once a day for 12
weeks. After treatment, total lipoprotein decreased from 231.6 to
220 mg/dL; low-density lipoprotein cholesterol decreased from
142.9 to 131.3 mg/dL. Brachial artery flow-mediated dilatation, a
marker of endothelial function, improved after treatment, prob-
ably because of increased FT4.28 Changes in coagulation and fi-
brinolytic cascade are related to SHypo, and might explain
increased risk of stroke in those under 65 years observed in
SHypo.9
SHyper, on the other hand, might be accompanied by changes in
the coagulation cascade that increase the risk of thrombosis, although
it is unclear if this risk is clinically relevant.12
Effects of T3 on cardiomyocytes
Effects on gene transcription Direct effects on cytosol and
transmembrane proteins
Card
iomy
ocyte
Binding to the thyroid hormone
receptor in the nucleus
Activation of thyroid hormone
response elements
Direct modulation of transmembrane
ion channels, beta-adrenergic
receptors, adenylcyclase
+ -
Genes with positively regulated transcription:
alpha-myosine heavy chain, Na+/K+-ATPase,
sarcoplasmic reticulum Ca++-ATPase
Genes with negatively regulated transcription:
beta-myosine heavy chain, phospholamban,
Na+/Ca++-exchanger
Figure 2 Effect of T3 on the cardiomyocytes. T3, triiodothyronine.
Increased vascular resistance
Increased serum cholesterol
Impaired cardiac contractility
Impaired diastolic function
Palpitations
Atrial fibrillation
Systolic hypertension
Congestive heart failure
Decreased
T3, T4
Increased
T3, T4
HyperthyroidismHypothyroidism
Thyroid gland
Figure 3 Some mechanisms by which thyroid dysfunction affects
the cardiovascular system.
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..The international thyroid studies
collaboration
To better assess cardiovascular disease risk in subclinical thyroid dys-
function, we setup the ‘Thyroid Studies Collaboration”, an international
consortium that contributed individual participant data (IPD) from 18
prospective cohorts, including 73 000 participants across four contin-
ents.4,8–10,44 Few cases of central hyperthyroidism were excluded from
the analyses. For each cardiovascular outcome associated with SHypo
and SHyper, we updated our systematic review of the literature.4,8–10
IPD analyses allow analysis of specific subgroups with potentially differ-
ent risk profiles, while study-level meta-analyses may lead to aggregation
biases with spurious subgroup data.9 IPD analyses best pool evidence
across studies; they allow (i) increase statistical power, (ii) adjust for
similar confounding factors across studies, (iii) define similar TSH range,
and (iv) standardize definitions of clinical outcomes.45
Current evidence for association
between subclinical thyroid
dysfunction and cardiovascular
diseases
The Thyroid Studies Collaboration examined the association between
subclinical thyroid dysfunction and CHD events/mortality and HF, and
clarified conflicting data from earlier prospective cohorts.46–48
In a milestone IPD analysis of 11 prospective cohorts,4 6.2% of the
55 287 participants had SHypo, but the vast majority (n = 51 837)
were euthyroid. A total of 4470 participants developed CHD events,
among whom 430 (9.6%) had SHypo. Hazard ratios (HRs) for CHD
mortality were: 1.09 (95% CI, 0.91–1.30) with TSH 4.5 to 6.9 mIU/L;
1.42 (95% CI, 1.03–1.95) for TSH 7.0–9.9 mIU/L; and 1.58 (95% CI,
1.10–2.27; P = 0.005 for trend) for TSH > 10 mIU/L (Figure 4). SHypo
did not increase total mortality.
A similar IPD analysis on the association of SHypo and HF in 25
390 participants (8.1% with SHypo) found that HF risk increased
both with higher and lower TSH (P for quadratic pattern < 0.01)
(Figure 4); 2069 participants had HF events, of whom 250 (12.1%) had
SHypo and 57 (2.8%) SHyper.8
An IPD analysis with 52 674 participants from 10 cohorts (4.2%
with SHyper) showed an association between SHyper and total mor-
tality (HR 1.24, 95% CI, 1.06–1.46), CHD mortality (HR 1.29, 95% CI,
1.02–1.62), CHD events (HR 1.21, 95% CI, 0.99–1.46), and AF (HR
1.68, 95% CI, 1.16–2.43). 3,653 participants had CHD events, of
whom 108 (2.9%) had SHyper. In subgroup analyses of CHD mortal-
ity and AF, TSH < 0.10 mIU/L was associated with higher HR (2.54,
95% CI, 1.08–5.99).10 Finally, an IPD analysis of 47,573 individuals
from 17 cohorts (SHypo prevalence 0.4–16.3%, mean 7.3%) re-
ported increased risk of fatal stroke in SHypo for those 18–49-years
old (HR 4.22; 95% CI, 1.08–16.55) and 50–64-years old (HR 2.86;
95% CI, 1.31–6.26). A pattern of increased stroke risk for higher TSH
levels was identified: In age- and sex-adjusted analyses the HR for fatal
stroke was 1.18 (95% CI, 0.83–1.69) at TSH 4.5–6.9 mIU/L, 1.63 (95%
CI, 1.09–2.43) at TSH 7.0–9.9 mIU/L, and 1.69 (95% CI, 0.88–3.27) at
TSH 10.0–19.9 mIU/L.9
Figure 4 HRs for Coronary Heart Disease Mortality (black) and Heart Failure Event (red) based on TSH Levels (adapted from Refs. 4 and 8). Age-
and sex-adjusted HRs and their 95% CIs, presented by squares (reproduced with permission from Ref. 49).
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Impact of thyroid hormones
replacement on cardiac function
and cardiovascular imaging
Current data show several cardiac function parameters normalized in
patients treated for SHypo.
Levothyroxine in SHypo decreased the ratio between pre-ejection
period and LV ejection time decreased in 46 adults50 and improved car-
diac preload and contractility in 30 women.51 In 10 patients with SHypo,
IRT and the A wave dropped after treatment, and E/A ratio increased
(1.3 ± 0.3 to 1.7 ± 0.4, P < 0.001)36 (see Supplementary material online,
Table S1A). Studies were limited by small sample size, short duration,
non-standardized definitions of SHypo and echo measurements.
Impact of thyroid hormones
replacement on CIMT
Some evidence (see Supplementary material online, Table S1B) shows
CIMT regressed after thyroid function normalized. In a double-blind
controlled trial, levothyroxine reduced CIMT from 0.76 ± 0.14 to
0.67 ± 0.13 mm (P = 0.03).40 CIMT decreased from 0.67 ± 0.11 to
0.60 ± 0.10 mm (P = 0.02) in SHypo treated with levothyroxine for a
year.39 In a before–after trial including 34 patients with SHypo, CIMT
decreased, after a year of levothyroxine replacement, from 0.64 ±
0.02 to 0.55 ± 0.02 mm (P < 0.001), total cholesterol from 5.99 ±
0.25 to 4.80 ± 0.20 mmol/L (P < 0.001); and low-density lipopro-
tein cholesterol (LDL-C) from 3.65 ± 0.23 to 2.75 ± 0.19 mmol/L
(P = 0.005).41
Clinical issues for screening and
treatment of subclinical thyroid
dysfunction and the TRUST trial
Indications for screening and thresholds for treating SHypo and
SHyper are uncertain because randomized clinical trials (RCTs) with
relevant clinical outcomes are lacking52–54 and information on long-
term risks is limited.55 Current evidence is mostly based on observa-
tional studies, but also guidelines, expert committees and small
randomized trials which have systematically been reviewed by the US
Preventive Services Task Force (USPSTF) in 2015.56,57 Large random-
ized trials are needed to provide more evidence for screening and
treatment of subclinical thyroid dysfunction.
The TRUST Trial, a blinded multicentre RCT funded by the EU-
FP7 (Proposal 278148-2, ClinicalTrials.gov, NCT01660126), has been
set up to investigate the multi-modal impact of treatment on quality
of life and symptoms, and cardiovascular markers. Follow-up was
continued until the end of 2016, shedding light on thresholds and
benefits of levothyroxine in SHypo.
Recommendation for screening
based on current evidence
Current guidelines58,59 advocate measuring TSH for specific condi-
tions.4,8,49 Patients with previous thyroid disorder, hypothalamic-
pituitary disorder, and history of autoimmune disease could benefit
from TSH monitoring because they are at increased risk of overt
hypothyroidism.12 TSH testing could benefit those with abnormal val-
ues or changes in lipid profile,60 hyponatremia, unclear elevation of
creatinine kinase, anaemia, and thyroid altering medication since all
these laboratory findings are associated with higher risk of thyroid
dysfunction, especially hypothyroidism.61 According to the USPSTF,
there is currently insufficient evidence for weighing the benefits and
harms of early screening.56,57 The American Academy of Family
Physicians and the American College of Physicians (ACP) recom-
mend thyroid function be checked regularly in older women (>50
years for ACP). The American Thyroid Association (ATA) and the
American Association of Clinical Endocrinologists (AACE) advocate
assessing thyroid function in any patient at risk for hypothyroidism,
and measuring TSH in those >60.62
Recommendation for treatment
based on current evidence
Current recommended thresholds for starting thyroid hormone re-
placement are based on observational data and clinical trials with
short follow-up. Their results suggest a TSH treatment threshold >_
10 mIU/L,62 also recommended by the ATA and AACE. The decision
to treat TSH < 10 mIU/l should be taken individually, according to
the risk profile of each patient.62 Patients with cardiovascular dis-
order or at high risk of developing overt hypothyroidism might bene-
fit from earlier therapy,1,62 though opinions conflict.57 Some have
argued for the use of liothyronine (synthetic triiodothyronine), either
alone or in combination with levothyroxine, for better control of thy-
roid function; however, the current evidence is too short-term and
limited to recommend this form of treatment.63 Especially in older
people, overtreatment is common and can cause severe adverse
events like arrhythmia and HF exacerbation.64 According to the ATA
and AACE, treatment if TSH < 0.1 mIU/L might be reasonable in
high-risk patients, including those with cardiac arrhythmias, or post-
menopausal women at risk of or with known osteoporosis. In other
cases, careful clinical and 6-monthly laboratory follow-up seems
appropriate.52
Supplementary material
Supplementary material is available at European Heart Journal online.
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